Adipose-derived mesenchymal stem cells ameliorate STZ-induced pancreas damage in type 1 diabetes

Bio-Medical Materials and Engineering

Volumn 22, Issue 1-3, 2012, Pages 97-103

  Li, Yue Ying ^a   Liu, Han Han ^a   Chen, Hong Lei ^a   Li, Yin Ping ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Adipose; mesenchymal stem cells; pancreatic cells; type 1 diabetes

Indexed keywords

ADIPOSE; BALB/C MICE; BLOOD GLUCOSE; BLOOD GLUCOSE LEVEL; CELL DESTRUCTION; CONTROL GROUPS; IN-CONTROL; IN-VITRO; INTRAPERITONEALLY; MESENCHYMAL STEM CELL; PANCREATIC ISLET; PATHOLOGICAL CHANGES; SPRAGUE-DAWLEY RATS; TYPE 1 DIABETES;

BIOCHEMISTRY; BLOOD; CELL CULTURE; FLOW CYTOMETRY; GLUCOSE; HISTOLOGY; INSULIN; MAMMALS; TISSUE;

CELLS;

ANIMALIA; MUS; RATTUS;

STREPTOZOCIN;

ADIPOSE TISSUE; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL SEPARATION; CHEMICALLY INDUCED DISORDER; CYTOLOGY; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; PANCREAS; PANCREAS ISLET BETA CELL; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; CELL SEPARATION; DIABETES MELLITUS, TYPE 1; FEMALE; INSULIN-SECRETING CELLS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; PANCREAS; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 84863712959     PISSN: 09592989     EISSN: None     Source Type: Journal    
DOI: 10.3233/BME-2012-0694     Document Type: Conference Paper

References (19)

1. A. Rabinovitch, Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation. Diabetes 43(5) (1994), 613-621.
2. J.R. Lakey, M. Mirbolooki and A.M. Shapiro, Current status of clinical islet cell transplantation, Methods Mol. Biol. 333 (2006), 47-104.
3. G.Q. Daley and D.T. Scadden, Prospects for stem cell-based therapy, Cell 132(4) (2008), 544-548.
4. Y. Shi, G. Hu, J. Su et al., Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair, Cell Res. 20(5) (2010), 510-518.
5. A.J. Nauta and W.E. Fibbe, Immunomodulatory properties of mesenchymal stromal cells, Blood 110(10) (2007), 3499-3506.
6. M. Krampera, S. Glennie, J. Dyson et al., Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide, Blood 101(9) (2003), 3722-3729.
7. B.K. Le, I. Rasmusson, B. Sundberg et al., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet 363(9419) (2004), 1439-1441.
8. A. Augello, R. Tasso, S.M. Negrini, R. Cancedda and G. Pennesi, Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis, Arthritis Rheum. 56(4) (2007), 1175-1186.
9. A.M. Madec, R. Mallone, G. Afonso et al., Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells, Diabetologia 52(7) (2009), 1391-1399.
10. A.M. Parker and A.J. Katz, Adipose-derived stem cells for the regeneration of damaged tissues, Expert Opin. Biol. Ther. 6(6) (2006), 567-578.
11. G. Constantin, S. Marconi, B. Rossi et al., Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis, Stem Cells 27(10) (2009), 2624-2635.
12. M.A. Gonzalez, E. Gonzalez-Rey, L. Rico, D. Buscher and M. Delgado, Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells, Arthritis Rheum. 60(4) (2009), 1006-1019.
13. J. Xue, H. Chen, L. Diao, X. Chen and D. Xia, Expression of caveolin-1 in tongue squamous cell carcinoma by quantum dots, Eur. J. Histochem. 54(2) (2010), e20.
14. D. Kabelitz, E.K. Geissler, B. Soria, I.S. Schroeder, F. Fandrich and L. Chatenoud, Toward cell-based therapy of type I diabetes, Trends Immunol. 29(2) (2008), 68-74.
15. R. Yanez, M.L. Lamana, J. Garcia-Castro, I. Colmenero, M. Ramirez and J.A. Bueren, Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease, Stem Cells 24(11) (2006), 2582-2591.
16. J.W. Kang, K.S. Kang, H.C. Koo, J.R. Park, E.W. Choi and Y.H. Park, Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells, Stem Cells Dev. 17(4) (2008), 681-693.
17. Y.P. Li, S. Paczesny, E. Lauret et al., Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway, J. Immunol. 180(3) (2008), 1598-1608.
18. F. Gieseke, J. Bohringer, R. Bussolari, M. Dominici, R. Handgretinger and I. Muller, Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells, Blood 116(19) (2010), 3770-3779.
19. D. Shi, L. Liao, B. Zhang et al., Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1-mediated inhibition of NF-kappaB signaling, Exp. Hematol. 39(2) (2011), 214-224.